Omeros EBITDA 2012-2025 | OMER
Omeros ebitda from 2012 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
|
Omeros Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $-123 |
| 2024 | $-167 |
| 2023 | $-162 |
| 2022 | $-161 |
| 2021 | $-172 |
| 2020 | $-155 |
| 2019 | $-144 |
| 2018 | $-111 |
| 2017 | $-43 |
| 2016 | $-54 |
| 2015 | $-71 |
| 2014 | $-70 |
| 2013 | $-50 |
| 2012 | $-37 |
| 2011 | $-27 |
|
Omeros Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-12-31 | $-28 |
| 2025-09-30 | $-26 |
| 2025-06-30 | $-35 |
| 2025-03-31 | $-34 |
| 2024-12-31 | $-35 |
| 2024-09-30 | $-34 |
| 2024-06-30 | $-59 |
| 2024-03-31 | $-39 |
| 2023-12-31 | $-39 |
| 2023-09-30 | $-47 |
| 2023-06-30 | $-40 |
| 2023-03-31 | $-36 |
| 2022-12-31 | $-38 |
| 2022-09-30 | $-50 |
| 2022-06-30 | $-37 |
| 2022-03-31 | $-35 |
| 2021-12-31 | $-43 |
| 2021-09-30 | $-40 |
| 2021-06-30 | $-45 |
| 2021-03-31 | $-45 |
| 2020-12-31 | $-17 |
| 2020-09-30 | $-25 |
| 2020-06-30 | $-27 |
| 2020-03-31 | $-23 |
| 2019-12-31 | $-27 |
| 2019-09-30 | $-11 |
| 2019-06-30 | $-9 |
| 2019-03-31 | $-19 |
| 2018-12-31 | $-18 |
| 2018-09-30 | $-35 |
| 2018-06-30 | $-30 |
| 2018-03-31 | $-27 |
| 2017-12-31 | $-14 |
| 2017-09-30 | $-5 |
| 2017-06-30 | $-12 |
| 2017-03-31 | $-13 |
| 2016-12-31 | $-12 |
| 2016-09-30 | $-12 |
| 2016-06-30 | $-11 |
| 2016-03-31 | $-19 |
| 2015-12-31 | $-18 |
| 2015-09-30 | $-19 |
| 2015-06-30 | $-16 |
| 2015-03-31 | $-18 |
| 2014-12-31 | $-20 |
| 2014-09-30 | $-17 |
| 2014-06-30 | $-17 |
| 2014-03-31 | $-16 |
| 2013-12-31 | $-14 |
| 2013-09-30 | $-13 |
| 2013-06-30 | $-13 |
| 2013-03-31 | $-10 |
| 2012-12-31 | $-7 |
| 2012-09-30 | $-13 |
| 2012-06-30 | $-8 |
| 2012-03-31 | $-8 |
| 2011-12-31 | $-10 |
| 2011-09-30 | $-6 |
| 2011-06-30 | $-5 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.827B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $174.688B | 19.48 |
| Stryker (SYK) | United States | $129.889B | 24.88 |
| Medtronic (MDT) | Ireland | $111.968B | 15.57 |
| EssilorLuxottica (ESLOY) | France | $107.724B | 0.00 |
| Boston Scientific (BSX) | United States | $91.831B | 20.26 |
| Medline (MDLN) | United States | $59.904B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.712B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $33.391B | 15.98 |
| ResMed (RMD) | United States | $33.341B | 22.26 |
| Agilent Technologies (A) | United States | $32.516B | 20.44 |
| Koninklijke Philips (PHG) | Netherlands | $27.260B | 16.18 |
| Terumo (TRUMY) | Japan | $19.854B | 23.21 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.025B | 11.36 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.227B | 0.00 |
| Insulet (PODD) | United States | $13.640B | 39.54 |
| Baxter (BAX) | United States | $8.854B | 7.56 |
| Sunny Optical Technology (SNPTF) | China | $8.381B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.537B | 28.15 |
| Demant (WILYY) | Denmark | $6.395B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.247B | 15.90 |
| Envista Holdings (NVST) | United States | $4.301B | 21.99 |
| BillionToOne (BLLN) | United States | $3.729B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $3.666B | 0.00 |
| ICU Medical (ICUI) | United States | $3.141B | 20.47 |
| Prestige Consumer Healthcare (PBH) | United States | $2.676B | 12.62 |
| Haemonetics (HAE) | United States | $2.664B | 11.65 |
| LeMaitre Vascular (LMAT) | United States | $2.611B | 48.16 |
| Phibro Animal Health (PAHC) | United States | $2.347B | 20.67 |
| GN Store Nord (GNNDY) | Denmark | $2.270B | 21.90 |
| Neogen (NEOG) | United States | $2.050B | 44.86 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.028B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $1.794B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.654B | 32.89 |
| Curaleaf Holdings (CURLF) | Canada | $1.584B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.495B | 3.96 |
| AtriCure (ATRC) | United States | $1.429B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.386B | 15.91 |
| Kestra Medical Technologies (KMTS) | United States | $1.043B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.953B | 164.50 |
| QuidelOrtho (QDEL) | United States | $0.943B | 6.53 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.896B | 0.00 |
| InMode (INMD) | Israel | $0.857B | 9.40 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.789B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.766B | 0.00 |
| CeriBell (CBLL) | United States | $0.683B | 0.00 |
| Brainsway (BWAY) | Israel | $0.546B | 55.68 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 11.18 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.424B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.415B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.367B | 25.70 |
| SNDL (SNDL) | Canada | $0.366B | 0.00 |
| Cerus (CERS) | United States | $0.363B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.311B | 126.00 |
| Evolus (EOLS) | United States | $0.278B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.259B | 0.00 |
| MacroGenics (MGNX) | United States | $0.229B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Accendra Health (ACH) | United States | $0.215B | 2.96 |
| Utah Medical Products (UTMD) | United States | $0.210B | 18.94 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.194B | 57.17 |
| TerrAscend (TSNDF) | Canada | $0.193B | 0.00 |
| Organigram Global (OGI) | Canada | $0.191B | 0.00 |
| Apyx Medical (APYX) | United States | $0.166B | 0.00 |
| Quanterix (QTRX) | United States | $0.158B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.152B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.143B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.133B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.090B | 11.73 |
| Exagen (XGN) | United States | $0.073B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| ImmuCell (ICCC) | United States | $0.064B | 0.00 |
| Biote (BTMD) | United States | $0.063B | 3.46 |
| INLIF (INLF) | China | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.038B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.032B | 26.91 |
| United-Guardian (UG) | United States | $0.030B | 14.23 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Jin Medical (ZJYL) | China | $0.018B | 0.00 |
| Modular Medical (MODD) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |